CCM
LGND icon

Coe Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Coe Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9,724
Closed -$604K – 77
2019
Q3 		$604K Buy
9,724
+350
+4% +$22K 0.67% 57
2019
Q2 		$668K Sell
9,374
-66
-0.7% -$4.86K 0.74% 51
2019
Q1 		$740K Sell
9,440
-106
-1% -$8.03K 0.86% 42
2018
Q4 		$808K Sell
9,546
-1,523
-14% -$162K 0.99% 36
2018
Q3 		$1.9M Buy
11,069
+64
+0.6% +$9.65K 1.87% 20
2018
Q2 		$1.42M Hold
11,005
– – 1.58% 26
2018
Q1 		$1.13M Buy
11,005
+177
+2% +$17.5K 1.23% 36
2017
Q4 		$925K Sell
10,828
-337
-3% -$29.2K 0.98% 44
2017
Q3 		$948K Buy
+11,165
New +$884K 0.99% 41

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Coe Capital Management's LGND Position: Q4 2019 in Review

Coe Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2019, closing a stake of 9,724 shares — an estimated $604K sold.

Coe Capital Management first reported a position in LGND in Q3 2017 and held it in 9 quarters. The position peaked at $1.9M in Q3 2018. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

  • Coe Capital Management reported no remaining Ligand Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Coe Capital Management sold 9,724 Ligand Pharmaceuticals shares in Q4 2019, an estimated $604K.
  • Coe Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 9 quarters.
  • Coe Capital Management's Ligand Pharmaceuticals position peaked at $1.9M in Q3 2018.
  • 266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on Coe Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.